Anaconda ANA5 Funnel Catheter for Ischemic Stroke Approved in Europe

June 18, 2025—Anaconda Biomed, SL, announced that it has received CE Mark certification for its ANA5 advanced neurovascular access funnel catheter.

The CE Mark enables eventual commercial availability of the device across the European Union, noted Anaconda, a developer of neurothrombectomy devices based in Barcelona, Spain.

Anaconda noted that the ANA5 funnel catheter features a vessel-matching diameter funnel to maximize clot capture in mechanical thrombectomy. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The device’s unique geometry promotes clot capture and removal, stated the company.

CE Mark approval was supported by clinical data from the ANAIS study, which evaluated the safety and performance of the ANA funnel catheter in the endovascular treatment of acute ischemic stroke caused by large vessel occlusion. ANAIS demonstrated high reperfusion and first-pass success rates, noted Anaconda.

In April 2025, the company announced that the study was published by Alejandro Tomasello, MD, et al in American Journal of Neuroradiology (2025;46:502-509).

Anaconda advised that further clinical validation is ongoing in the prospective, multicenter ATHENA randomized trial, which is evaluating the impact of proximal flow arrest on reperfusion effectiveness to support future regulatory submissions and commercialization efforts in the United States. Commencement of enrollment in ATHENA was announced in April 2025.

The catheter is currently an investigational device and is not available for sale in the United States, stated the company.